Clinical Research Directory
Browse clinical research sites, groups, and studies.
Synbiotic Formula (SCV09) in Alzheimer's Disease Patients
Sponsor: Chinese University of Hong Kong
Summary
In recent years, emerging studies have revealed the role of gut microbiota in human health and diseases, including AD and other neurodegenerative conditions5. Although the underlying mechanism is still largely unknown, successful therapies targeting the gut-brain axis may serve as indirect evidence of the possible linkage. This pilot, single-arm study aims to estimate the efficacy and assess the safety profile of the use of a new synbiotic formula (SCV09) in improving dementia-related behaviour in Alzheimer's disease patients, paving the way for a large-scale randomised controlled trial in the future.
Official title: A Pilot, Single-arm Study on the Efficacy and Safety of the Use of a Synbiotic Formula (SCV09) in Alzheimer's Disease Patients
Key Details
Gender
All
Age Range
60 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-05-15
Completion Date
2026-12-15
Last Updated
2025-09-03
Healthy Volunteers
No
Conditions
Interventions
SCV09
SCV09 consists of a blend of four probiotic species from the Bifidobacterium and Lactobacillus genera (20 billion CFU in 1 sachet per day), prebiotic compounds including galacto-oligosaccharides, xylo-oligosaccharides and inulin, vitamin B6, B9, B12 and vitamin D.
Locations (1)
The Chinse University of Hong Kong
Shatin, Hong Kong